Shenzhen Salubris Pharmaceuticals

Historical price data

Founded in 1998, Shenzhen Salubris Pharmaceuticals has grown from a domestic manufacturer into a Chinese biopharmaceutical leader with a significant public valuation. Its mission centers on addressing critical healthcare needs in chronic diseases through a dual strategy of high-quality generic production and innovative drug development. Key achievements include establishing dominant market positions in cardiovascular and metabolic segments, building a robust pipeline with several late-stage assets, and maintaining consistent profitability to fund R&D. The company's strategy focuses on deepening its therapeutic moats, expanding its innovative portfolio, and navigating the evolving Chinese pharmaceutical reimbursement landscape.

Integrated platform encompassing advanced drug formulation, biosimilar development, and large-scale GMP manufacturing, enabling full control from API synthesis to finished product.

Competes with large domestic pharma peers (e.g., Hengrui, CSPC) in innovation and a fragmented generic market on cost. Faces intensifying competition from multinational corporations (MNCs) who are deepening their localization efforts in China. Salubris differentiates through its integrated model, deep commercial reach in lower-tier cities, and a broad portfolio for chronic disease management.